Evidence map›Paper›PMID 39139818›Full record

ArticleFrontiers in genetics2024

Sara L Cook, Christian Stout, Lindsey Kirkeby, Noemi Vidal-Folch, Devin Oglesbee, Linda Hasadsri, Duygu Selcen, Margherita Milone, Daniel Anderson, Nathan P Staff

Abstract read
In one paragraph

Article in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara L CookDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Christian StoutDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Lindsey KirkebyCenter for Regenerative Medicine, Mayo Clinic, Rochester, MN, United States.
Noemi Vidal-FolchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Devin OglesbeeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Linda HasadsriDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
Duygu SelcenDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.
Margherita MiloneDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.
Daniel AndersonDepartment of Neurology, Mayo Clinic Health System, La Crosse, WI, United States.
Nathan P StaffDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Spinal muscular atrophy (SMA) is caused by homozygous loss of the Methods: We identified two patients with mild SMA caused by a heterozygous deletion of Results: Two patients with slowly progressing mild weakness were confirmed to have heterozygous pathogenic missense variant c.5C>G and a heterozygous deletion of Conclusions: These case reports reinforce that the rare c.5C>G variant causes mild disease. Furthermore, the analysis of SMA nuclear gems in patient samples supports the theory that the p.Ala2Gly SMN can form partially functional SMN complexes that may carry out essential cellular functions and result in mild disease.

Indexed as

c.5C>Gdiagnostic testingexon 1nuclear gemsp.Ala2GlySMN1spinal muscular atrophy

Identifiers

PMID39139818
PMCPMC11319185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.